SITC Announces Keynote Speakers Dr. Susan Kaech and Dr. Robert D. Schreiber at its 38^th Annual Meeting

The Society for Immunotherapy of Cancer (SITC) is excited to announce Susan Kaech, PhD, from Salk Institute as the Keynote Speaker at its 38^th Annual Meeting and Pre-Conference Programs. The title of her presentation is “Stressing Out the Immune System in Cancer.” SITC is also hosting Robert D. Schreiber, PhD, FAIO, Washington School of Medicine, the 2023 recipient of the Richard V. Smalley Memorial Award and Lectureship, the society’s most prestigious award and which honors those who have been pioneers in their work and made a notable impact on the field of cancer immunotherapy. Dr. Schreiber will also give a presentation as a part of this award.

Read More >>

Latest Press Releases

5/22/23−FDA Grants Accelerated Approval to Epcoritamab-bysp for Relapsed or Refractory Diffuse Large B-cell Lymphoma

5/10/23−SITC Announces Keynote Speakers Dr. Susan Kaech and Dr. Robert D. Schreiber at its 38th Annual Meeting

4/6/23−FDA Grants Accelerated Approval to Enfortumab Vedotin-ejfv with Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma

3/23/23−FDA Grants Accelerated Approval to Retifanlimab-dlwr for Metastatic Merkel Cell Carcinoma

1/27/23 –FDA Approves Pembrolizumab as Adjuvant Treatment for Non-Small Cell Lung Cancer

11/11/22 –FDA Approves Tremelimumab in Combination with Durvalumab and Platinum-Based Chemotherapy for Metastatic Non-Small Cell Lung Cancer

11/10/22 –FDA Approves Cemiplimab-rwlc in Combination with Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer

11/3/22 –SITC to Hold Press Briefing on Nine Abstracts to be Presented at 37th Annual Meeting

11/2/22 –SITC 2022 Late-Breaking Abstracts Announced

10/26/22 –FDA Approves Teclistamab-cqyv for Relapsed or Refractory Multiple Myeloma

10/25/22 – FDA Approves Tremelimumab in Combination with Durvalumab for unresectable hepatocellular carcinoma

10/7/22 – The Society for Immunotherapy of Cancer (SITC) Publishes a Checklist to Maximize the Benefit to Patients for Clinical Trials in Immuno-oncology

10/5/22 – Black and African American Professionals Discuss Barriers in Biomedical Field

9/8/22 – Oncology News Burst from FDA: durvalumab

8/30/22– SITC Announces Annual Award Recipients

8/11/22– SITC Forward Fund Announces 2022 Fellowships and Tech Award Recipients

7/12/2022 – SITC to Convene Oncology Leaders to Address Crisis in Clinical Research at Virtual Summit

5/18/22 – SITC Announces Keynote Speaker Dr. Padmanee Sharma and Keynote Panel Honoring the Work of Dr. Zelig Esshar at its 37^th Annual Meeting

5/10/22 – SITC’s Steven A. Rosenberg Scholars Award: $150,000 in Funding for an Emerging Leader in Immuno-Oncology

4/26/22 – Cancer Researchers to Rock Buddy Guy’s Legends for One Night Only

3/9/22 – Oncology News Burst from FDA: Nivolumab

1/13/22 – SITC to Offer Program for Emerging Leaders in Cancer Immunotherapy Focused on Accelerating Professional Development and Innovative Collaborations

SITC Communications
communications@sitcancer.org
+1 414-271-2456